Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00304421 · ClinicalTrials.gov registry record · Phase 4
Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD
A Phase 4 study, sponsored by VA Greater Los Angeles Healthcare System.
- Completed
- Registry status
- Phase 4
- Development phase
- 23
- Enrollment target
NCT00304421: Completed Phase 4 study, sponsored by VA Greater Los Angeles Healthcare System.
NCT00304421 is a Phase 4 study that has completed, run by VA Greater Los Angeles Healthcare System. The registered enrollment target is 23 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00304421, a Phase 4 study, has completed, sponsored by VA Greater Los Angeles Healthcare System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the effect of two different drugs, rabeprazole (20 mg) and pantoprazole (40 mg), and their effects on the amount of acid produced by your stomach on evening and at night after standard protein meal.
Interventions
- DRUG pantoprazole
- DRUG rabeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2004-01 |
| Est. Completion | 2007-09 |
| Phase | Phase 4 |
What the finished NCT00304421 record still lists
NCT00304421 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which pantoprazole is the first listed.
NCT00304421 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00304421 about?
NCT00304421 is a clinical study titled "Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD". The purpose of the study is to compare the effect of two different drugs, rabeprazole (20 mg) and pantoprazole (40 mg), and their effects on the amount of acid produced by your stomach on evening and at night after standard protein meal.
What is the current status of trial NCT00304421?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2004-01. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00304421?
The interventions under investigation include: pantoprazole (DRUG), rabeprazole (DRUG).
Who is sponsoring clinical trial NCT00304421?
This trial is sponsored by VA Greater Los Angeles Healthcare System, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00304421's enrollment target sits among peer trials
23 1725th of 2000 higher than 270 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia